Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
325 articles by Michael Gibney
-
How Trump’s war in Iran is scrambling pharma’s shipping options
April 2, 2026 -
Big Pharma goes nuts over food allergies — again
March 31, 2026 -
VC sees early signs of a biotech market spring as long winter fades
March 17, 2026 -
New FDA guidance could elevate pharma’s biosimilar market
March 12, 2026 -
Servier’s $2.5B cancer bet underlines a quick oncology growth strategy
March 10, 2026 -
Cancer tests are becoming more precise and guiding pharma R&D
March 5, 2026 -
J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks
March 3, 2026 -
Biohaven says FDA roadblocks leave rare disease patients in limbo
Feb. 26, 2026 -
Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.
Feb. 19, 2026 -
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
Feb. 12, 2026 -
A protein model designed for space could expand pharma’s definition of ‘druggability’
Feb. 11, 2026 -
Big Pharma CEOs set sights on massive growth in years to come
Feb. 5, 2026 -
Investors crave safer, market-ready biotech bets, widening the early-stage funding gap
Feb. 3, 2026 -
Politicization runs deeper than ever at FDA, risking long-term impacts
Jan. 29, 2026 -
A potential gene therapy for heart failure is an approach decades in the making
Jan. 27, 2026 -
US drug pricing policies are ‘red lights’ for investors, and China beckons
Jan. 22, 2026 -
It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?
Jan. 15, 2026 -
3 positive trends for Massachusetts’ biopharma sector
Jan. 13, 2026 -
Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?
Jan. 8, 2026 -
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
Dec. 19, 2025 -
5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.
Dec. 16, 2025 -
Pharma’s top deals in 2025
Dec. 11, 2025 -
How Lilly uses Big Pharma heft to lift up-and-coming biotechs
Dec. 9, 2025 -
BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
Dec. 4, 2025 -
Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons
Dec. 2, 2025
